A post-marketing surveillance study has revealed no new evidence to suggest that the new measles mumps and rubella virus (MMR) vaccine [Priorix]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1150, 2007-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Measles, Mumps, Rubella Vaccine (Priorix™; GSK-MMR): A Review of its Use in the Prevention of Measles, Mumps and Rubella

By Wellington K.   Goa K.L.  

Drugs, Vol. 63, Iss. 19, 2003-01 ,pp. : 2107-2126

Adis International

Access to resources Recommend Favorite

Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra ™ )

By Dhillon Sohita   Curran Monique P.  

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 337-347

Adis International

Access to resources Recommend Favorite

Measles, mumps and rubella (MMR) vaccine appears to be highly effective in the military setting

By  

Inpharma, Vol. 1, Iss. 1262, 2000-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

A Case Study of a Graphical Misrepresentation: Drawing the Wrong Conclusions about the Measles, Mumps and Rubella Virus Vaccine

By Cox Anthony R.   Kirkham Harold  

Drug Safety, Vol. 30, Iss. 10, 2007-01 ,pp. : 831-836

Adis International

Access to resources Recommend Favorite

Measles mumps and rubella virus vaccine: Encephalitis in paediatric patients: case report

By  

Reactions Weekly, Vol. 1, Iss. 1336, 2011-01 ,pp. : 33-33

Adis International

Access to resources Recommend Favorite